Zobrazeno 1 - 10
of 326
pro vyhledávání: ''
Autor:
Edouard Dezamis, Gilles Huberfeld, Johan Pallud, Alessandro Moiraghi, Martine Gavaret, Frédéric Dhermain, Fabrice Chrétien, Marc Zanello, Eléonore Guinard, Pascale Varlet, Alexandre Roux, Catherine Oppenheim, Sophie Peeters
Publikováno v:
Neurology
Neurology, 2021, pp.10.1212/WNL.0000000000013005. ⟨10.1212/WNL.0000000000013005⟩
Neurology, American Academy of Neurology, 2021, pp.10.1212/WNL.0000000000013005. ⟨10.1212/WNL.0000000000013005⟩
Neurology, 2021, pp.10.1212/WNL.0000000000013005. ⟨10.1212/WNL.0000000000013005⟩
Neurology, American Academy of Neurology, 2021, pp.10.1212/WNL.0000000000013005. ⟨10.1212/WNL.0000000000013005⟩
Background and ObjectivesThe association between levetiracetam and survival with isocitrate dehydrogenase (IDH) wild-type glioblastomas is controversial. We investigated whether the duration of levetiracetam use during the standard chemoradiation pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5123f633788d8696485a10689ed2b832
https://www.hal.inserm.fr/inserm-03421138
https://www.hal.inserm.fr/inserm-03421138
Autor:
Roberto Salvatori, Maria Fleseriu, Aart Jan van der Lely, Thierry Brue, Michael Wajnrajch, Dagmar Führer-Sakel, Roy Gomez, Judith Hey-Hadavi, Andrew Palladino, Laura De Marinis, Srinivas Rao Valluri, Cecilia Camacho-Hübner, Joli van der Lans-Bussemaker
Publikováno v:
European Journal of Endocrinology
European Journal of Endocrinology, 2021, 185 (4), pp.525-538. ⟨10.1530/EJE-21-0239⟩
European Journal of Endocrinology, 2021, 185 (4), pp.525-538. ⟨10.1530/EJE-21-0239⟩
Objective To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY. Design Global (15 countries), multicentre, non-interventional study (2004–2017). Methods The complete ACRO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bd8c4bf1c0d81597f7c9ee3d9cb24a
https://hal-amu.archives-ouvertes.fr/hal-03586286
https://hal-amu.archives-ouvertes.fr/hal-03586286
Autor:
Didier Blaise, Tycel Phillips, Jason T. Romancik, Roch Houot, Robert Lowsky, Martina Sollini, Jean Marc Schiano De Colella, Amer Beitinjaneh, Gunjan L. Shah, Lazaros J. Lekakis, Stephen D. Smith, Paolo Corradini, Mohamad Mohty, Maryam Rahimian, Luca Castagna, Taiga Nishihori, Asad Bashey, Talha Badar, Reid W. Merryman, Mehdi Hamadani, Carmelo Carlo-Stella, Dipenkumar Modi, Sally Arai, Kamal Bouabdallah, Valter Torri, Joseph P. McGuirk, Guillaume Manson, Anna Guidetti, Yi-Bin Chen, Hatcher J. Ballard, Julio C. Chavez, Pier Luigi Zinzani, Tatyana Feldman, Sunita Nathan, Anurag K. Singh, Massimo Magagnoli, Marie Pierre Moles-Moreau, Beatrice Casadei, Anthony Serritella, Michael Byrne, Radhakrishnan Ramchandren, Miguel-Angel Perales, Chiara De Philippis, Samantha Jaglowski, Justin Kline, Remy Dulery, Laura Giordano, Alex F. Herrera, Jonathon B. Cohen, Philippe Armand, Armando Santoro, Aspasia Stamatoulas, Stephen M. Ansell, Michael A. Spinner, Lori Dahncke, Corentin Orvain, Chloé Spilleboudt, Geoffrey Shouse, Robin Joyce, Vincent T. Ho, Matthew J. Frigault, Ryan C. Lynch, Uttam Rao, Jakub Svoboda, David A. Bond, Yago Nieto
Publikováno v:
Leukemia
Leukemia, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
Leukemia, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
International audience; Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35becb5c5a55058afd6585d16fefe3a8
https://univ-rennes.hal.science/hal-03229516
https://univ-rennes.hal.science/hal-03229516
Publikováno v:
Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, Wiley, 2021, 35 (4), pp.751-761. ⟨10.1111/fcp.12612⟩
Fundamental & Clinical Pharmacology, Wiley, 2021, 35 (4), pp.751-761. ⟨10.1111/fcp.12612⟩
Doctor shopping enables subjects to receive more than the prescribed dose out of any medical management, which suggests a search for high doses and makes doctor shopping a relevant proxy for misuse and potential abuse. Therefore, this study aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cde0249a75e7aa0a594011d7affeb87
https://hal.archives-ouvertes.fr/hal-03620648
https://hal.archives-ouvertes.fr/hal-03620648
Autor:
Frédéric Marchal, Christophe Pomel, Emmanuel Barranger, Laurence Gladieff, Alexandre de Nonneville, Florence Joly, Aude-Marie Savoye, Hèlène Costaz, Jean-Marc Classe, Anne Floquet, Patricia Pautier, Isabelle Ray-Coquard, Roman Rouzier, Gaëtane Simon, Thibault De La Motte Rouge, Christophe Zemmour, C. Courtinard, Renaud Sabatier, Sophie Frank, Baptiste Sauterey, Pierre-Emmanuel Colombo, Thierry Petit, Cécile Guillemet, Eric Leblanc
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2021, ⟨10.1016/j.ygyno.2021.07.019⟩
Gynecologic Oncology, Elsevier, 2021, ⟨10.1016/j.ygyno.2021.07.019⟩
Gynecologic Oncology, 2021, 163 (1), pp.64-71. ⟨10.1016/j.ygyno.2021.07.019⟩
Gynecologic Oncology, 2021, ⟨10.1016/j.ygyno.2021.07.019⟩
Gynecologic Oncology, Elsevier, 2021, ⟨10.1016/j.ygyno.2021.07.019⟩
Gynecologic Oncology, 2021, 163 (1), pp.64-71. ⟨10.1016/j.ygyno.2021.07.019⟩
Prognostic significance of endometrioid epithelial ovarian cancer (EOC) is controversial. We compared clinical, pathological, and biological features of patients with endometrioid and serous EOC, and assessed the independent effect of histology on ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1468d0a85f8ccc774ac2d57478c4563f
https://hal.science/hal-03345277
https://hal.science/hal-03345277
Autor:
Martine Escoffre-Barbe, P. Rousselot, Pascale Cony-Makhoul, Stéphane Bouchet, Lambert Busque, Caroline Dartigeas, Franck E. Nicolini, Valérie Coiteux, Françoise Huguet, Laurence Legros, Lydia Roy, Delphine Rea, François Guilhot, Joelle Guilhot, Emilie Cayssials, Francois-Xavier Mahon, Luigina Mollica, Agnès Guerci, Martine Gardembas, Jean-Michel Cayuela, Anne Bergeron, Gabriel Etienne, Viviane Dubruille, Aude Charbonnier, Mathieu Molimard
Publikováno v:
British Journal of Haematology
British Journal of Haematology, Wiley, 2021, 194 (2), pp.393-402. ⟨10.1111/bjh.17654⟩
British Journal of Haematology, 2021, 194 (2), pp.393-402. ⟨10.1111/bjh.17654⟩
British Journal of Haematology, Wiley, 2021, 194 (2), pp.393-402. ⟨10.1111/bjh.17654⟩
British Journal of Haematology, 2021, 194 (2), pp.393-402. ⟨10.1111/bjh.17654⟩
International audience; Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion (PlEff). We rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccf07937e7bb76172bb58c0cabbf6bd0
https://hal.archives-ouvertes.fr/hal-03324903
https://hal.archives-ouvertes.fr/hal-03324903
Autor:
Patrick Gérardin, Malik Boukerrou, Cécile Saint Pastou Terrier, Fanny Andry, Y. Koumar, Loic Raffray, Antoine Bertolotti, N. Bouscaren, Roxane Begnis, Marie-Pierre Moiton
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, BioMed Central, 2021, 21 (1), pp.482. ⟨10.1186/s12879-021-06193-6⟩
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Infectious Diseases, BioMed Central, 2021, 21 (1), pp.482. ⟨10.1186/s12879-021-06193-6⟩
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-5 (2021)
Background Mycoplasma genitalium (MG) is an emerging sexually transmitted infection (STI) for whose management remains controversial. We aimed to assess the prevalence and risk factors of MG infection in patients attending an STI clinic in Reunion Is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ec7385aaf1a05e8aec8dd736f8d310
https://www.hal.inserm.fr/inserm-03313563
https://www.hal.inserm.fr/inserm-03313563
Autor:
Véronique Frémeaux-Bacchi, Christiane Mousson, Emma Allain Launay, David Ribes, François Provôt, Simon Ville, Aurélie Le Thuaut, Claire Presne, Anne-Laure Sellier-Leclerc, Aurélie Hummel, Ferielle Louillet, Leila Tricot, Marc Fila, Quentin Raimbourg, Stéphane Bally, Fadi Fakhouri, Eric Rondeau, Ariane Zaloszyc, Moglie Le Quintrec, Djamal Djeddi, William Hanf, Guillaume Favre, Annie Lahoche, Valérie Châtelet, Sophie Caillard, Chantal Loirat, Jean-Philippe Coindre, Claire Pouteil-Noble, Yahsou Delmas, Olivia Boyer
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (18), pp.2438-2449. ⟨10.1182/blood.2020009280⟩
Blood, American Society of Hematology, 2021, 137 (18), pp.2438-2449. ⟨10.1182/blood.2020009280⟩
The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open-label study to assess eculizumab discontinuation in children and adul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105ee1348fd54e8d802db81dde74df0a
https://hal.umontpellier.fr/hal-03222627
https://hal.umontpellier.fr/hal-03222627
Autor:
Vassiliki Karantza, Kenji Tamura, Xuan Zhou, Eric P. Winer, Seock-Ah Im, Jaime Mejia, Isabell Witzel, Nadia Harbeck, A. Gonçalves, Rebecca Dent, Stefania Zambelli, Laura Testa, Peter Schmid, Shoichiro Ohtani, Keun Seok Lee, Oleg Lipatov, Javier Cortes, Nicholas C. Turner, Eva Muñoz-Couselo, Fabrice Andre
Publikováno v:
Lancet Oncology
Lancet Oncology, 2021, 22 (4), pp.499-511. ⟨10.1016/S1470-2045(20)30754-3⟩
Lancet Oncology, 2021, 22 (4), pp.499-511. ⟨10.1016/S1470-2045(20)30754-3⟩
Pembrolizumab showed durable antitumour activity and manageable safety in metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 trials. In this study, we compared pembrolizumab with chemotherapy for second-line or thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49802cd31756dcf686cf9480c3f647ac
https://hal.science/hal-03629997
https://hal.science/hal-03629997
Autor:
Mathieu Chappuy, Mikail Nourredine, Fadi Meroueh, Benjamin Rolland, Jérôme Bachellier, Patrick Bendimerad, Georges Brousse, Peter Hjelmström, Philippe Nubukpo, Margaux Kosim, Benoit Trojak
Publikováno v:
Drug and Alcohol Dependence
Drug and Alcohol Dependence, Elsevier, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩
Drug and Alcohol Dependence, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩
Drug and Alcohol Dependence, Elsevier, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩
Drug and Alcohol Dependence, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩
International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e170b11df0b49854bec1a6085fa5f9d
https://hal.sorbonne-universite.fr/hal-03280782/file/1-s2.0-S0376871620306578-main.pdf
https://hal.sorbonne-universite.fr/hal-03280782/file/1-s2.0-S0376871620306578-main.pdf